REFERENCES
1. Vergaro G, Aimo A, Barison A, et al. Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings. Eur J Prev Cardiol 2020;27:1806-15.
2. Nienhuis HL, Bijzet J, Hazenberg BP. The prevalence and management of systemic amyloidosis in western countries. Kidney Dis (Basel) 2016;2:10-9.
3. Simões MV, Fernandes F, Marcondes-braga FG, et al. Posicionamento sobre diagnóstico e tratamento da amiloidose cardíaca - 2021. Arquivos Brasileiros de Cardiologia 2021;117:561-98.
4. Debonnaire P, Claeys M, De Smet M, et al. Trends in diagnosis, referral, red flag onset, patient profiles and natural outcome of de novo cardiac amyloidosis and their multidisciplinary implications. Acta Cardiol ;2021:1-14.
5. Oubari S, Naser E, Papathanasiou M, et al. Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement. Eur J Haematol 2021;107:449-57.
6. Elsayed M, Usher S, Habib MH, et al. Current updates on the management of AL amyloidosis. J Hematol 2020;10:147-61.
7. Biliński J, Biernacka EK, Januszewicz A. Cardiac amyloidosis secondary to multiple myeloma: successful sequential cardiac and autologous stem cell transplantations with excellent outcome. Eur Heart J 2021;42:3803.
8. Comenzo RL, Reece D, Palladini G, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 2012;26:2317-25.
9. Tahir UA, Doros G, Kim JS, et al. Predictors of mortality in light chain cardiac amyloidosis with heart failure. Sci Rep 2019;9:8552.
10. Palladini G, Milani P, Merlini G. Management of AL amyloidosis in 2020. Hematology Am Soc Hematol Educ Program 2020;2020:363-71.
11. Frustaci A, Galea N, Verardo R, et al. Kappa-light chain amyloid overlapping hypertrophic cardiomyopathy with myocardial noncompaction. Circ Cardiovasc Imaging 2020;13:e010379.
12. Kumar SK, Gertz MA, Lacy MQ, et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc 2011;86:12-8.
13. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation 2017;135:1357-77.
15. Vaidya GN, Patel JK, Kittleson M, et al. Intermediate-term outcomes of heart transplantation for cardiac amyloidosis in the current era. Clin Transplant 2021;35:e14308.
16. Hosenpud JD, Uretsky BF, Griffith BP, et al. Successful intermediate-term outcome for patients with cardiac amyloidosis undergoing heart transplantation: results of a multicentre survey. J Heart Transplant 1990;9:346-50.
17. Conner R, Hosenpud JD, Norman DJ, et al. Heart transplantation for cardiac amyloidosis: successful one-year outcome despite recurrence of the disease. J Heart Transplant 1988;7:165-7
18. Kpodonu J, Massad MG, Caines A, Geha AS. Outcome of heart transplantation in patients with amyloid cardiomyopathy. J Heart Lung Transplant 2005;24:1763-5.
19. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004;140:85-93.
20. Gillmore JD, Goodman HJ, Lachmann HJ, et al. Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood 2006;107:1227-9.
21. Kristen AV, Sack FU, Schonland SO, et al. Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis. Eur J Heart Fail 2009;11:1014-20.
22. Okamoto S, Zhao Y, Lindqvist P, et al. Development of cardiomyopathy after liver transplantation in Swedish hereditary transthyretin amyloidosis (ATTR) patients. Amyloid 2011;18:200-5.
23. Sickels A, Shah KB, Ruch B, et al. Combined heart-liver and domino liver transplantation in familial amyloidosis. Am Surg 2021:31348211023427.
24. Rosenbaum AN, AbouEzzeddine OF, Grogan M, et al. Outcomes after cardiac transplant for wild type transthyretin amyloidosis. Transplantation 2018;102:1909-13.
25. Mehra MR, Canter CE, Hannan MM, et al. International Society for Heart Lung Transplantation (ISHLT) Infectious Diseases. The 2016 international society for heart lung transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant 2016;35:1-23.
26. Roig E, Almenar L, Gonzalez-Vilchez F, et al. Outcomes of heart transplantation for cardiac amyloidosis: subanalysis of the Spanish registry for heart transplantation. Am J Transplant 2009;9:1414-9.
27. Lacy MQ, Dispenzieri A, Hayman SR, et al. Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy. J Heart Lung Transplant 2008;27:823-9.
28. Ohiomoba RO, Youmans QR, Ezema A, et al. Cardiac transplantation outcomes in patients with amyloid cardiomyopathy. Am Heart J 2021;236:13-21.
29. Di Nora C, Sponga S, Ferrara V, et al. Emerging therapy in light-chain and acquired transthyretin-related amyloidosis: an Italian single-centre experience in heart transplantation. J Cardiovasc Med (Hagerstown) 2021;22:261-7.
30. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th international symposium on amyloid and amyloidosis, tours, France, 18-22 April 2004. Am J Hematol 2005;79:319-28.
31. Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012;30:4541-9.
32. Kristen AV, Kreusser MM, Blum P, et al. Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era. J Heart Lung Transplant 2018;37:611-8.
33. Garcia-Pavia P, Bengel F, Brito D, et al. Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. Eur J Heart Fail 2021;23:895-905.
34. Obici L, Kuks JB, Buades J, et al. European Network for TTR-FAP (ATTReuNET). Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis. Curr Opin Neurol 2016;29 Suppl 1:S27-35.
35. Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European society of cardiology working group on myocardial and pericardial diseases. Eur J Heart Fail 2021;23:512-26.
36. Davis MK, Lee PH, Witteles RM. Changing outcomes after heart transplantation in patients with amyloid cardiomyopathy. J Heart Lung Transplant 2015;34:658-66.
37. Maurer MS, Schwartz JH, Gundapaneni B, et al. ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018;379:1007-16.
38. Müller ML, Butler J, Heidecker B. Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy? Eur J Heart Fail 2020;22:39-53.
39. Di Nora C, Miani D, D’Elia AV, et al. Heart transplantation in Danon disease: Long term single centre experience and review of the literature. Eur J Med Genet 2020;63:103645.
40. Di Nora C, Paldino A, Miani D, et al. Heart transplantation in kearns-sayre syndrome. Transplantation 2019;103:e393-4.
41. Di Nora C, Livi U. Heart transplantation in cardiac storage diseases: data on Fabry disease and cardiac amyloidosis. Curr Opin Organ Transplant 2020;25:211-7.
42. Maurer MS, Raina A, Hesdorffer C, et al. Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure. Transplantation 2007;83:539-45.
43. Dubrey SW, Burke MM, Hawkins PN, Banner NR. Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant 2004;23:1142-53.
44. Grogan M, Gertz M, McCurdy A, et al. Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: the Mayo clinic experience. World J Transplant 2016;6:380-8.
45. Barrett CD, Alexander KM, Zhao H, et al. Outcomes in patients with cardiac amyloidosis undergoing heart transplantation. JACC Heart Fail 2020;8:461-8.
